230 related articles for article (PubMed ID: 19128200)
1. Selective antagonism at dopamine D3 receptors as a target for drug addiction pharmacotherapy: a review of preclinical evidence.
Heidbreder C
CNS Neurol Disord Drug Targets; 2008 Nov; 7(5):410-21. PubMed ID: 19128200
[TBL] [Abstract][Full Text] [Related]
2. Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders.
Heidbreder CA; Newman AH
Ann N Y Acad Sci; 2010 Feb; 1187():4-34. PubMed ID: 20201845
[TBL] [Abstract][Full Text] [Related]
3. Rationale in support of the use of selective dopamine D₃ receptor antagonists for the pharmacotherapeutic management of substance use disorders.
Heidbreder C
Naunyn Schmiedebergs Arch Pharmacol; 2013 Feb; 386(2):167-76. PubMed ID: 23104235
[TBL] [Abstract][Full Text] [Related]
4. Selective dopamine D3 receptor antagonists: a review 2001-2005.
Micheli F; Heidbreder C
Recent Pat CNS Drug Discov; 2006 Nov; 1(3):271-88. PubMed ID: 18221209
[TBL] [Abstract][Full Text] [Related]
5. Current Perspectives on Selective Dopamine D
Newman AH; Xi ZX; Heidbreder C
Curr Top Behav Neurosci; 2023; 60():157-201. PubMed ID: 35543868
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological actions of NGB 2904, a selective dopamine D3 receptor antagonist, in animal models of drug addiction.
Xi ZX; Gardner EL
CNS Drug Rev; 2007; 13(2):240-59. PubMed ID: 17627675
[TBL] [Abstract][Full Text] [Related]
7. The dopamine D3 receptor, a quarter century later.
Sokoloff P; Le Foll B
Eur J Neurosci; 2017 Jan; 45(1):2-19. PubMed ID: 27600596
[TBL] [Abstract][Full Text] [Related]
8. Selective antagonism at dopamine D3 receptors prevents nicotine-triggered relapse to nicotine-seeking behavior.
Andreoli M; Tessari M; Pilla M; Valerio E; Hagan JJ; Heidbreder CA
Neuropsychopharmacology; 2003 Jul; 28(7):1272-80. PubMed ID: 12700694
[TBL] [Abstract][Full Text] [Related]
9. Dopamine D3 receptor antagonists: a patent review (2007 - 2012).
Micheli F; Heidbreder C
Expert Opin Ther Pat; 2013 Mar; 23(3):363-81. PubMed ID: 23282131
[TBL] [Abstract][Full Text] [Related]
10. Dopamine D3 receptor ligands for drug addiction treatment: update on recent findings.
Le Foll B; Collo G; Rabiner EA; Boileau I; Merlo Pich E; Sokoloff P
Prog Brain Res; 2014; 211():255-75. PubMed ID: 24968784
[TBL] [Abstract][Full Text] [Related]
11. A novel dopamine D3 receptor antagonist YQA14 inhibits methamphetamine self-administration and relapse to drug-seeking behaviour in rats.
Chen Y; Song R; Yang RF; Wu N; Li J
Eur J Pharmacol; 2014 Nov; 743():126-32. PubMed ID: 25261038
[TBL] [Abstract][Full Text] [Related]
12. The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence.
Heidbreder CA; Gardner EL; Xi ZX; Thanos PK; Mugnaini M; Hagan JJ; Ashby CR
Brain Res Brain Res Rev; 2005 Jul; 49(1):77-105. PubMed ID: 15960988
[TBL] [Abstract][Full Text] [Related]
13. Activation of central neurotensin receptors reinstates cocaine seeking in the rat: modulation by a D1/D5, but not D2/D3, receptor antagonist.
Lopak V; Erb S
Psychopharmacology (Berl); 2005 Oct; 182(2):297-304. PubMed ID: 16010538
[TBL] [Abstract][Full Text] [Related]
14. Medication discovery for addiction: translating the dopamine D3 receptor hypothesis.
Newman AH; Blaylock BL; Nader MA; Bergman J; Sibley DR; Skolnick P
Biochem Pharmacol; 2012 Oct; 84(7):882-90. PubMed ID: 22781742
[TBL] [Abstract][Full Text] [Related]
15. A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development. Focus on GBR 12909.
Rothman RB; Glowa JR
Mol Neurobiol; 1995; 11(1-3):1-19. PubMed ID: 8561954
[TBL] [Abstract][Full Text] [Related]
16. Selective antagonism at dopamine D3 receptors attenuates cocaine-seeking behaviour in the rat.
Cervo L; Cocco A; Petrella C; Heidbreder CA
Int J Neuropsychopharmacol; 2007 Apr; 10(2):167-81. PubMed ID: 16426478
[TBL] [Abstract][Full Text] [Related]
17. Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis.
Keck TM; John WS; Czoty PW; Nader MA; Newman AH
J Med Chem; 2015 Jul; 58(14):5361-80. PubMed ID: 25826710
[TBL] [Abstract][Full Text] [Related]
18. The importance of the adenosine A(2A) receptor-dopamine D(2) receptor interaction in drug addiction.
Filip M; Zaniewska M; Frankowska M; Wydra K; Fuxe K
Curr Med Chem; 2012; 19(3):317-55. PubMed ID: 22335511
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the transport, metabolism, and pharmacokinetics of the dopamine D3 receptor-selective fluorenyl- and 2-pyridylphenyl amides developed for treatment of psychostimulant abuse.
Mason CW; Hassan HE; Kim KP; Cao J; Eddington ND; Newman AH; Voulalas PJ
J Pharmacol Exp Ther; 2010 Jun; 333(3):854-64. PubMed ID: 20228156
[TBL] [Abstract][Full Text] [Related]
20. The dopamine D3 receptor and drug dependence: effects on reward or beyond?
Le Foll B; Goldberg SR; Sokoloff P
Neuropharmacology; 2005 Sep; 49(4):525-41. PubMed ID: 15963538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
